Brief: Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting Potential Of Nicotinamide Riboside (NR) For Werner Syndrome, A Rare Genetic Disorder
09/06/2025 15:07
June 9 (Reuters) - Niagen Bioscience Inc NAGE.O: NIAGEN BIOSCIENCE ANNOUNCES FIRST-EVER PEER-REVIEWED STUDY HIGHLIGHTING THE POTENTIAL OF NICOTINAMIDE RIBOSIDE (NR) FOR WERNER SYNDROME, A RARE GENETIC DISORDER Source text: ID:nBw188W8Ca Further company coverage: NAGE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Niagen Bioscience
See all newsAs weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Niagen Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Niagen Bioscience Q2 net sales fall, missing estimates
Niagen Bioscience Inc expected to post earnings of 2 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce